Citius Oncology, Inc. (CTOR) vs Telomir Pharmaceuticals, Inc. Common Stock (TELO)

A side-by-side comparison of Citius Oncology, Inc. and Telomir Pharmaceuticals, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Citius Oncology, Inc. logo
CTOR
Citius Oncology, Inc.
$81M
$0.87HealthcareDelayed quote: Oct 6, 2026, 3:59 PM EDT
Telomir Pharmaceuticals, Inc. Common Stock logo
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$83M
$1.20HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CTOR vs TELO

growth of $100 · dividends reinvested · last 2y
CTOR -92.4% (-72.4%/yr)TELO -70.0% (-45.2%/yr)TELO compounded faster over this window
0100200300Start $10020252026$8$30
CTOR TELO

CTOR vs TELO: by the numbers

  • •TELO is the larger company ($83M vs $81M market cap).
  • •Both run net losses; TELO's is the smaller (0.00% vs -648.32% net margin).

Metrics side by side

Valuation

MetricCTORTELO
Forward P/E8.69N/A
P/S ratio11.37N/A
P/B ratio2.0016.40

Profitability

MetricCTORTELO
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin-648.32%0.00%
ROE-114.06%-116.74%
ROIC-88.72%-120.93%

Go deeper

Full CTOR analysisFull TELO analysisInteractive comparison tool

Dig into the metrics

Citius Oncology ROETelomir Pharmaceuticals, Inc. Common Stock ROECitius Oncology operating marginTelomir Pharmaceuticals, Inc. Common Stock operating marginCitius Oncology revenue growthTelomir Pharmaceuticals, Inc. Common Stock revenue growthCitius Oncology free cash flowTelomir Pharmaceuticals, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.